Jan. 24 at 11:34 PM
Commercial-stage oncology focused biopharma valuations & analyst consensus revenue estimates. We're only sharing our analysis. This is not investment advice.
We added
$CORT to this list for the first time after its relacorliant showed impressive Phase 3 data in ovarian cancer (after getting rejected for Cushing's Disease on New Year's Eve). Immunogen's Elahere for ovarian was acquired within 13 months of approval. CORT's Korlym was approved for Cushing's Disease in 2012.
$SNDX trading at 1.8X FY29 estimates continues to appear to be a good value for INCY which trades at 4.4X (or even 3.8X using INCY's EV).
$IOVA guided to
$250 to
$300MM for FY25 suggesting Q425 was
$73 t0
$123. Consensus is
$82MM. We could be wrong but IOVA's valuation does not appear to reflect TIL's opportunity in lung.
$VSTM is trading at a 6-month low after announcing meaningful management changes last month. Nonetheless, Jeffries says their combo drug could do
$700MM at peak
$AUTL ?
